Expert Statement: Alex Del Priore, Syngene
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Chemistry
Expert Statement: Chad Telgenhof, Sterling Pharma Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Thomas Otto and Peter Soelkner, Vetter
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Rohtash Kumar, Veranova
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Tom Wilson, Pfizer
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Federico Pollano, Rentschler
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Davuluri Saharsh Rao, Neuland Labs
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Prasad Raje, LGM Pharma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Gordon Bates, Lonza
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Kenneth N. Drew, Flamma
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Ludwig de Mot, EuroAPI
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Russel Miller, Enzene
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Frank Wegener, ESIM Chemicals
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: David McErlane and Aris Gennadios, Catalent
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Ashu Tandon, Aragen
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Tom Sellig, Adare Pharma Solutions
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
Expert Statement: Gavin Murdoch, Abzena
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
The Evolution of the CDMO Industry.
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
Sustainable Practices in Biopharmaceuticals
BioPhorum, an industry collaboration group, focuses on advancing sustainability within the biopharmaceutical sector. In an exclusive interview, Nicola Coles, Director of BioPhorum Sustainability, shares insights into the organization’s commitment to environmentally responsible practices.
Sustainability from the Beginning
The idea that statistics can address urgent sustainability concerns at the lab bench was central to presentations at the recent JMP Discovery Summit Europe in Manchester, UK.
Securing Supply Chains and Strengthening Partnerships
Interview with Edgardo Hernandez, President Manufacturing, Lilly
Integrated Continuous Manufacturing in Pharmaceuticals
An innovative manufacturing platform called integrated continuous manufacturing (ICM) represents a completely modernized model for drug manufacturing. In contrast to batch processes, ICM’s unique operational advantages will allow for cost-competitive end-to-end manufacturing and enable a more robust and responsive supply chain for critical drugs.
A New Standard of Collaboration for the Pharmaceutical Industry
Headquartered in Cramlington, UK, Sterling Pharma Solutions is a contract development and manufacturing organization (CDMO) that provides a range of services to the global biopharmaceutical industry, including active pharmaceutical ingredient (API) development, scale-up and cGMP manufacturing, as well as antibody drug conjugate (ADC) R&D and clinical-scale GMP manufacturing.
The Future of mRNA Technology
mRNA-based vaccines against the coronavirus have become firmly established in medicine since the pandemic. Nevertheless, the technology is still at the beginning of its potential. Experts see a wide range of potential applications for this relatively new technology, particularly in infectious diseases and cancer.
AI-Powered Knowledge Transfer in Manufacturing
Artificial intelligence (AI) can help companies in the process industry capture, retain and access valuable historical expertise and ease the transition for new colleagues in the plant.
Unleashing Sustainable Innovation, Navigating Business, and Pioneering a Greener Future
In today’s world, where environmental sustainability is at the forefront of global concerns, green chemistry stands as a beacon of hope. This field focuses on inventing sustainable solutions that mitigate the harmful impact of traditional chemical processes.
The Green Power of Catalysis
With more than 80% of all chemical products manufactured using catalytic processes, catalysts are the number one value generator in the chemical industry.
Packaging Industry Drives Circular Economy through Science, Innovation and Consumer Insights
The concept of a circular economy, where materials are recycled and reused, is becoming increasingly important in consumer packaging, driven by regulatory requirements and customer interest.
Spray Drying for Inhalation: the Challenges of Scale-up
When developing an inhaled powder formulation, the drug particles’ properties are critical to successful delivery to the deep lung. The aerodynamic diameter is the key parameter, as it represents how well the particle flies in an air stream.
The Use of Evonik’s Catalysts to Manufacture TFA-free Margarines
When manufacturing specialty edible fats, ensuring that the product has the desired properties – such as a stable shelf life, optimal melting behavior, and texture – is essential.
Providing Solutions by Making the Most of Biomedical Data
Many life science companies generate large swathes of data.
How CDMOs Can Contribute to Pharma Supply even Better
The demand for medicines is increasing rapidly and R&D pipelines have doubled over the last decade.
Bakelite Acquires LRBG Chemicals
Bakelite Synthetics, the US manufacturer of phenolic resins and adhesives, acquires LRBG Chemicals, a Canadian manufacturer and developer of resins based in Longueuil, Quebec.
Johnson Matthey Set to Catalyze the Net Zero Transition
Johnson Matthey (JM) looks back at a legacy of 200+ years. Established in 1817, the London, England-based chemical company reported annual revenues of about €18 billion in 2022. JM has built a global presence with operations in more than 30 countries. The company’s strategy is based on the vision for a cleaner, healthier world and mirrors society’s need to create a more sustainable future. JM has set out to catalyze the net zero transition by delivering sustainable solutions to customers enabled by innovative technology and leading positions in JM’s key markets automotive, chemicals, and energy. To get a better understanding of the role JM’s technological developments play for a sustainable future, Michael Reubold spoke with Maurits van Tol, the company’s Chief Technology Officer.
